JP2022538449A5 - - Google Patents

Info

Publication number
JP2022538449A5
JP2022538449A5 JP2021577871A JP2021577871A JP2022538449A5 JP 2022538449 A5 JP2022538449 A5 JP 2022538449A5 JP 2021577871 A JP2021577871 A JP 2021577871A JP 2021577871 A JP2021577871 A JP 2021577871A JP 2022538449 A5 JP2022538449 A5 JP 2022538449A5
Authority
JP
Japan
Prior art keywords
rilpivirine
pharmaceutically acceptable
acceptable salt
subject
equivalent amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021577871A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538449A (ja
Filing date
Publication date
Priority claimed from US16/919,677 external-priority patent/US20210000823A1/en
Application filed filed Critical
Publication of JP2022538449A publication Critical patent/JP2022538449A/ja
Publication of JP2022538449A5 publication Critical patent/JP2022538449A5/ja
Priority to JP2026018065A priority Critical patent/JP2026097814A/ja
Withdrawn legal-status Critical Current

Links

JP2021577871A 2019-07-03 2020-07-03 リルピビリンを用いて小児患者におけるhivを治療する方法 Withdrawn JP2022538449A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026018065A JP2026097814A (ja) 2019-07-03 2026-02-05 リルピビリンを用いて小児患者におけるhivを治療する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962870413P 2019-07-03 2019-07-03
US62/870,413 2019-07-03
US16/919,677 US20210000823A1 (en) 2019-07-03 2020-07-02 Methods of treating hiv
US16/919,677 2020-07-02
PCT/EP2020/068913 WO2021001568A1 (en) 2019-07-03 2020-07-03 Methods of treating hiv in pediatric patients with rilpivirine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026018065A Division JP2026097814A (ja) 2019-07-03 2026-02-05 リルピビリンを用いて小児患者におけるhivを治療する方法

Publications (2)

Publication Number Publication Date
JP2022538449A JP2022538449A (ja) 2022-09-02
JP2022538449A5 true JP2022538449A5 (cg-RX-API-DMAC7.html) 2023-07-10

Family

ID=71579550

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2021577856A Withdrawn JP2022538338A (ja) 2019-07-03 2020-07-02 リルピビリンを用いて小児患者におけるhivを治療する方法
JP2021577871A Withdrawn JP2022538449A (ja) 2019-07-03 2020-07-03 リルピビリンを用いて小児患者におけるhivを治療する方法
JP2026018065A Pending JP2026097814A (ja) 2019-07-03 2026-02-05 リルピビリンを用いて小児患者におけるhivを治療する方法
JP2026018074A Pending JP2026097815A (ja) 2019-07-03 2026-02-05 リルピビリンを用いて小児患者におけるhivを治療する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021577856A Withdrawn JP2022538338A (ja) 2019-07-03 2020-07-02 リルピビリンを用いて小児患者におけるhivを治療する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2026018065A Pending JP2026097814A (ja) 2019-07-03 2026-02-05 リルピビリンを用いて小児患者におけるhivを治療する方法
JP2026018074A Pending JP2026097815A (ja) 2019-07-03 2026-02-05 リルピビリンを用いて小児患者におけるhivを治療する方法

Country Status (14)

Country Link
US (3) US20210000823A1 (cg-RX-API-DMAC7.html)
EP (2) EP3993799A1 (cg-RX-API-DMAC7.html)
JP (4) JP2022538338A (cg-RX-API-DMAC7.html)
KR (2) KR20220028049A (cg-RX-API-DMAC7.html)
CN (2) CN114126655A (cg-RX-API-DMAC7.html)
AU (2) AU2020300818A1 (cg-RX-API-DMAC7.html)
BR (2) BR112021026916A2 (cg-RX-API-DMAC7.html)
CA (1) CA3144307A1 (cg-RX-API-DMAC7.html)
IL (1) IL289457A (cg-RX-API-DMAC7.html)
JO (1) JOP20210347A1 (cg-RX-API-DMAC7.html)
MA (2) MA56449A (cg-RX-API-DMAC7.html)
MX (2) MX2022000060A (cg-RX-API-DMAC7.html)
PH (1) PH12021553288A1 (cg-RX-API-DMAC7.html)
WO (2) WO2021001508A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA56449A (fr) * 2019-07-03 2022-05-11 Janssen Sciences Ireland Unlimited Co Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
AR065720A1 (es) * 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
NZ610729A (en) * 2010-11-19 2015-10-30 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
CA2921336A1 (en) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
EP4233846B1 (en) * 2015-06-30 2024-12-04 Gilead Sciences, Inc. Pharmaceutical formulations
MA46563B1 (fr) * 2016-10-24 2024-01-31 Janssen Sciences Ireland Unlimited Co Compositions dispersibles
RU2755710C2 (ru) * 2017-06-30 2021-09-20 Вайв Хелткер Компани Комбинация, ее применение и способы лечения с использованием указанной комбинации
MA56449A (fr) * 2019-07-03 2022-05-11 Janssen Sciences Ireland Unlimited Co Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine

Similar Documents

Publication Publication Date Title
Javorac et al. An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment
JP6196041B2 (ja) 大うつ病を有する患者において減量療法を提供する方法
KR20260046169A (ko) Hiv의 치료 및 예방을 위한 레나카파비르 주간 투여 레지먼
Taha et al. Parenteral patent drug S/GSK1265744 has the potential to be an effective agent in pre-exposure prophylaxis against HIV infection
US20190151307A1 (en) Methods of treating patients co-infected with a virus and tuberculosis
KR20260057463A (ko) Hiv 캡시드 저해제의 투여 레지먼
JP2021004249A5 (cg-RX-API-DMAC7.html)
AU2018291076A1 (en) Combination and uses and treatments thereof
JP2022538338A5 (cg-RX-API-DMAC7.html)
WO2019016679A1 (en) Combination drug therapy
US10758531B2 (en) Regimens and compositions for treating HIV infections and AIDS
AU2018239257B2 (en) HIV post-exposure prophylaxis
Dinh et al. An updated overview on long-acting therapeutics for the prevention and treatment of human immunodeficiency virus (HIV) from a perspective of pharmaceutics
RU2022102380A (ru) Способы лечения инфекции, вызванной вич, у пациентов детского возраста с применением рилпивирина
Kobayashi et al. A case of under-dosing after raltegravir formulation change in an elderly patient treated for HIV
CA3054822C (en) Hiv post-exposure prophylaxis
EP3664895A1 (en) Combinations and uses and treatments thereof
Francisco Data Released from Startmrk Study of Isentress Versus Efavirenz
Bowersox ACTG 343: three drugs better than two for maintaining HIV suppression
JP2019508399A (ja) 多くの治療を経験したhiv−1に感染した個体において使用するためのホステムサビル
EA049592B1 (ru) СПОСОБ ЛЕЧЕНИЯ РНК ВИРУСНЫХ ИНФЕКЦИЙ, В ТОМ ЧИСЛЕ COVID-19 (SARS-CoV-2)
US20230158020A1 (en) Method for treating RNA viral infections, including COVID-19 (SARS-CoV-2)
AU2020318808A1 (en) HIV pre-exposure prophylaxis
TW201726133A (zh) Hiv成熟抑制劑調配物
JP2020529461A (ja) 組み合わせ並びにその使用及び治療